Enlivex Therapeutics Ltd
ENLV
查看详细走势图
0.965USD
-0.125-11.43%
交易中 （美东）报价延迟15分钟
343.45K总市值
0.04市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-11.43%
5天
-5.35%
1月
-16.05%
6月
-4.42%
今年开始到现在
+37.29%
1年
-5.35%
查看详细走势图
TradingKey Enlivex Therapeutics Ltd股票评分
单位: USD 更新时间: 2026-03-27操作建议
Enlivex Therapeutics Ltd当前公司基本面数据相对谨慎，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名190/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价13.00。中期看，股价处于上升通道。近一个月，市场表现较差，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
Enlivex Therapeutics Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Enlivex Therapeutics Ltd亮点
亮点风险
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值0.04，处于3年历史高位
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值313.63K
活跃度增加
近期活跃度增加，过去20天平均换手率5.81
分析师目标
根据
2
位分析师
买入
评级
13.000
目标均价
+1092.66%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Enlivex Therapeutics Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Enlivex Therapeutics Ltd简介
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
公司代码ENLV
公司Enlivex Therapeutics Ltd
CEOHershkovitz (Oren)
网址https://www.enlivex.com/
相关品种
